WO2019144912A1 - β-内酰胺酶抑制剂及其用途 - Google Patents
β-内酰胺酶抑制剂及其用途 Download PDFInfo
- Publication number
- WO2019144912A1 WO2019144912A1 PCT/CN2019/073000 CN2019073000W WO2019144912A1 WO 2019144912 A1 WO2019144912 A1 WO 2019144912A1 CN 2019073000 W CN2019073000 W CN 2019073000W WO 2019144912 A1 WO2019144912 A1 WO 2019144912A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxo
- octane
- cyclopropane
- bicyclo
- diazaspiro
- Prior art date
Links
- 239000003781 beta lactamase inhibitor Substances 0.000 title abstract description 11
- 229940126813 beta-lactamase inhibitor Drugs 0.000 title abstract description 11
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 76
- 150000003839 salts Chemical class 0.000 claims abstract description 26
- 150000002148 esters Chemical class 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 14
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 286
- 229950011148 cyclopropane Drugs 0.000 claims description 187
- 125000000217 alkyl group Chemical group 0.000 claims description 181
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 84
- 239000002253 acid Substances 0.000 claims description 74
- -1 (1R,4S)-4-(5-(indolylmethyl)-1,3,4-oxadiazol-2-yl)-6-oxo-5,7-diazaspiro[bicyclo[ 3.2.1] octane-2,1'-cyclopropane]-7-ylsulfuric acid Chemical compound 0.000 claims description 64
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 39
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 37
- 239000011734 sodium Substances 0.000 claims description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 29
- 125000006239 protecting group Chemical group 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 23
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 23
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 23
- 241000894006 Bacteria Species 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 125000002619 bicyclic group Chemical group 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 14
- LPCWKMYWISGVSK-UHFFFAOYSA-N bicyclo[3.2.1]octane Chemical compound C1C2CCC1CCC2 LPCWKMYWISGVSK-UHFFFAOYSA-N 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 230000003115 biocidal effect Effects 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 208000019206 urinary tract infection Diseases 0.000 claims description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 5
- 235000010290 biphenyl Nutrition 0.000 claims description 5
- 239000004305 biphenyl Substances 0.000 claims description 5
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical group C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 claims description 4
- 229930186147 Cephalosporin Natural products 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 241000186359 Mycobacterium Species 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- 201000007100 Pharyngitis Diseases 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 150000003973 alkyl amines Chemical class 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 229940124587 cephalosporin Drugs 0.000 claims description 4
- 150000001780 cephalosporins Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 4
- 229940049954 penicillin Drugs 0.000 claims description 4
- 229910052705 radium Inorganic materials 0.000 claims description 4
- 229910052701 rubidium Inorganic materials 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 claims description 3
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 3
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical group C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims description 3
- 208000005141 Otitis Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 3
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 3
- 208000019258 ear infection Diseases 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000193755 Bacillus cereus Species 0.000 claims description 2
- 208000031729 Bacteremia Diseases 0.000 claims description 2
- 241000606124 Bacteroides fragilis Species 0.000 claims description 2
- 208000004020 Brain Abscess Diseases 0.000 claims description 2
- NCJSAHSVFBCDRY-IUCAKERBSA-N C1CC12C[C@H](N3C[C@@H]2NC3=O)C4=NOC=C4 Chemical compound C1CC12C[C@H](N3C[C@@H]2NC3=O)C4=NOC=C4 NCJSAHSVFBCDRY-IUCAKERBSA-N 0.000 claims description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
- 241000589876 Campylobacter Species 0.000 claims description 2
- 208000004672 Cardiovascular Infections Diseases 0.000 claims description 2
- 208000014912 Central Nervous System Infections Diseases 0.000 claims description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 claims description 2
- 241000588923 Citrobacter Species 0.000 claims description 2
- 241000588919 Citrobacter freundii Species 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 241000588697 Enterobacter cloacae Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 208000001860 Eye Infections Diseases 0.000 claims description 2
- 206010048461 Genital infection Diseases 0.000 claims description 2
- 241000606768 Haemophilus influenzae Species 0.000 claims description 2
- 241000590002 Helicobacter pylori Species 0.000 claims description 2
- 208000036209 Intraabdominal Infections Diseases 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims description 2
- 208000032376 Lung infection Diseases 0.000 claims description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 241000588621 Moraxella Species 0.000 claims description 2
- 241001508003 Mycobacterium abscessus Species 0.000 claims description 2
- 241000186367 Mycobacterium avium Species 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 2
- 241000588650 Neisseria meningitidis Species 0.000 claims description 2
- 206010048685 Oral infection Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010033078 Otitis media Diseases 0.000 claims description 2
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 2
- 241000588767 Proteus vulgaris Species 0.000 claims description 2
- 206010037596 Pyelonephritis Diseases 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 241000607768 Shigella Species 0.000 claims description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 2
- 206010062255 Soft tissue infection Diseases 0.000 claims description 2
- 241000122973 Stenotrophomonas maltophilia Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 2
- 208000006374 Uterine Cervicitis Diseases 0.000 claims description 2
- 206010046914 Vaginal infection Diseases 0.000 claims description 2
- 201000008100 Vaginitis Diseases 0.000 claims description 2
- 241000607626 Vibrio cholerae Species 0.000 claims description 2
- XYBOBLYKARPREG-BQBZGAKWSA-N [(2S,5R)-2-(1,3,4-oxadiazol-2-yl)-7-oxospiro[1,6-diazabicyclo[3.2.1]octane-4,1'-cyclopropane]-6-yl] hydrogen sulfate Chemical compound [H][C@]12CN([C@@H](CC11CC1)C1=NN=CO1)C(=O)N2OS(O)(=O)=O XYBOBLYKARPREG-BQBZGAKWSA-N 0.000 claims description 2
- DYYVOFNFDIWIHT-IUCAKERBSA-N [(2S,5R)-2-(azetidin-3-ylcarbamoyl)-7-oxospiro[1,6-diazabicyclo[3.2.1]octane-4,1'-cyclopropane]-6-yl] hydrogen sulfate Chemical compound [H][C@]12CN([C@@H](CC11CC1)C(=O)NC1CNC1)C(=O)N2OS(O)(=O)=O DYYVOFNFDIWIHT-IUCAKERBSA-N 0.000 claims description 2
- NCDCTZAKNJQSFS-UWVGGRQHSA-N [(2S,5R)-2-[5-(aminomethyl)-1,2-oxazol-3-yl]-7-oxospiro[1,6-diazabicyclo[3.2.1]octane-4,1'-cyclopropane]-6-yl] hydrogen sulfate Chemical compound C1CC12C[C@H](N3C[C@@H]2N(C3=O)OS(=O)(=O)O)C4=NOC(=C4)CN NCDCTZAKNJQSFS-UWVGGRQHSA-N 0.000 claims description 2
- NIJOHHJHKSSGOR-BQBZGAKWSA-N [(2S,5R)-2-[5-(aminomethyl)-1,3,4-oxadiazol-2-yl]-7-oxospiro[1,6-diazabicyclo[3.2.1]octane-4,1'-cyclopropane]-6-yl] hydrogen sulfate Chemical compound [H][C@]12CN([C@@H](CC11CC1)C1=NN=C(CN)O1)C(=O)N2OS(O)(=O)=O NIJOHHJHKSSGOR-BQBZGAKWSA-N 0.000 claims description 2
- VVMRMDCYQHZPRL-STQMWFEESA-N [(2S,5R)-2-[5-(azetidin-3-ylmethyl)-1,2-oxazol-3-yl]-7-oxospiro[1,6-diazabicyclo[3.2.1]octane-4,1'-cyclopropane]-6-yl] hydrogen sulfate Chemical compound [H][C@]12CN([C@@H](CC11CC1)C1=NOC(CC3CNC3)=C1)C(=O)N2OS(O)(=O)=O VVMRMDCYQHZPRL-STQMWFEESA-N 0.000 claims description 2
- DWHHZWNWAFHVGP-QWRGUYRKSA-N [(2S,5R)-2-[5-(methylaminomethyl)-1,2-oxazol-3-yl]-7-oxospiro[1,6-diazabicyclo[3.2.1]octane-4,1'-cyclopropane]-6-yl] hydrogen sulfate Chemical compound [H][C@]12CN([C@@H](CC11CC1)C1=NOC(CNC)=C1)C(=O)N2OS(O)(=O)=O DWHHZWNWAFHVGP-QWRGUYRKSA-N 0.000 claims description 2
- FRNJDYUWPJBENQ-STQMWFEESA-N [(2S,5R)-2-[5-[(azetidin-3-ylamino)methyl]-1,2-oxazol-3-yl]-7-oxospiro[1,6-diazabicyclo[3.2.1]octane-4,1'-cyclopropane]-6-yl] hydrogen sulfate Chemical compound [H][C@]12CN([C@@H](CC11CC1)C1=NOC(CNC3CNC3)=C1)C(=O)N2OS(O)(=O)=O FRNJDYUWPJBENQ-STQMWFEESA-N 0.000 claims description 2
- HHCVENHZUQFIFD-QWRGUYRKSA-N [(2S,5R)-7-oxo-2-[5-(2-oxopiperazin-1-yl)-1,2-oxazol-3-yl]spiro[1,6-diazabicyclo[3.2.1]octane-4,1'-cyclopropane]-6-yl] hydrogen sulfate Chemical compound C1CC12C[C@H](N3C[C@@H]2N(C3=O)OS(=O)(=O)O)C4=NOC(=C4)N5CCNCC5=O HHCVENHZUQFIFD-QWRGUYRKSA-N 0.000 claims description 2
- 150000001345 alkine derivatives Chemical class 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 229910001424 calcium ion Inorganic materials 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 206010008323 cervicitis Diseases 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 206010014801 endophthalmitis Diseases 0.000 claims description 2
- 208000011323 eye infectious disease Diseases 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 208000007565 gingivitis Diseases 0.000 claims description 2
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 2
- 229940037467 helicobacter pylori Drugs 0.000 claims description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 2
- 208000008494 pericarditis Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229910001414 potassium ion Inorganic materials 0.000 claims description 2
- 229940007042 proteus vulgaris Drugs 0.000 claims description 2
- 206010040872 skin infection Diseases 0.000 claims description 2
- 229910001415 sodium ion Inorganic materials 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 229910052721 tungsten Inorganic materials 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 210000003708 urethra Anatomy 0.000 claims description 2
- 229940118696 vibrio cholerae Drugs 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- 241000589291 Acinetobacter Species 0.000 claims 1
- 206010060968 Arthritis infective Diseases 0.000 claims 1
- 241000606153 Chlamydia trachomatis Species 0.000 claims 1
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- VABJRAWGKLRQFH-UHFFFAOYSA-N S(=O)(=O)(ON1CN2CCC3(CC3)C1C2)O Chemical compound S(=O)(=O)(ON1CN2CCC3(CC3)C1C2)O VABJRAWGKLRQFH-UHFFFAOYSA-N 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims 1
- 229940038705 chlamydia trachomatis Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010033072 otitis externa Diseases 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 327
- 239000000243 solution Substances 0.000 description 225
- 235000019439 ethyl acetate Nutrition 0.000 description 153
- 238000003786 synthesis reaction Methods 0.000 description 146
- 230000015572 biosynthetic process Effects 0.000 description 142
- 239000000203 mixture Substances 0.000 description 101
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 96
- 239000007787 solid Substances 0.000 description 86
- 238000004128 high performance liquid chromatography Methods 0.000 description 80
- 238000005481 NMR spectroscopy Methods 0.000 description 78
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 77
- 239000012043 crude product Substances 0.000 description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 42
- 239000012071 phase Substances 0.000 description 42
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 34
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- 238000002953 preparative HPLC Methods 0.000 description 32
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
- 239000013078 crystal Substances 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 229940125904 compound 1 Drugs 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 27
- 239000002904 solvent Substances 0.000 description 27
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 25
- 239000000543 intermediate Substances 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 24
- 239000000047 product Substances 0.000 description 22
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 20
- 239000000741 silica gel Substances 0.000 description 20
- 229910002027 silica gel Inorganic materials 0.000 description 20
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000003818 flash chromatography Methods 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 17
- 0 CCCC=C(C)CCCC(C(C*)CC1C(CC)CC1C)(C(C)(C)*C)C(C)(C)C(CC1)CC1=C(C)CC Chemical compound CCCC=C(C)CCCC(C(C*)CC1C(CC)CC1C)(C(C)(C)*C)C(C)(C)C(CC1)CC1=C(C)CC 0.000 description 15
- 230000001580 bacterial effect Effects 0.000 description 15
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 14
- 229960000723 ampicillin Drugs 0.000 description 14
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 14
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 14
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 14
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 14
- 229960000484 ceftazidime Drugs 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 14
- 229960002182 imipenem Drugs 0.000 description 14
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 102000006635 beta-lactamase Human genes 0.000 description 13
- 229940125898 compound 5 Drugs 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- 229940125782 compound 2 Drugs 0.000 description 12
- 229940126214 compound 3 Drugs 0.000 description 12
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 10
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- 108090000204 Dipeptidase 1 Proteins 0.000 description 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 8
- 239000012230 colorless oil Substances 0.000 description 8
- 239000013058 crude material Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 239000006150 trypticase soy agar Substances 0.000 description 7
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 239000007821 HATU Substances 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 108020004256 Beta-lactamase Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 150000001340 alkali metals Chemical class 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 239000011345 viscous material Substances 0.000 description 4
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 3
- 229960004261 cefotaxime Drugs 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- GLOKJCXNVOJHMP-STQMWFEESA-N (2S,5R)-7-oxo-6-phenylmethoxyspiro[1,6-diazabicyclo[3.2.1]octane-4,1'-cyclopropane]-2-carboxylic acid Chemical compound C([C@H](N1C[C@@H]2N(C1=O)OCC=1C=CC=CC=1)C(=O)O)C12CC1 GLOKJCXNVOJHMP-STQMWFEESA-N 0.000 description 2
- BMYNFMYTOJXKLE-REOHCLBHSA-N (2s)-3-azaniumyl-2-hydroxypropanoate Chemical compound [NH3+]C[C@H](O)C([O-])=O BMYNFMYTOJXKLE-REOHCLBHSA-N 0.000 description 2
- DXYNQSROMABIPK-YFKPBYRVSA-N (6S)-5-azaspiro[2.4]heptane-5,6-dicarboxylic acid Chemical compound C1N(C(O)=O)[C@H](C(=O)O)CC11CC1 DXYNQSROMABIPK-YFKPBYRVSA-N 0.000 description 2
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- JJCAYTVAYSGVLA-UHFFFAOYSA-N 2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCC(O)C(O)=O JJCAYTVAYSGVLA-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BOVGQOZVWBFHBX-UHFFFAOYSA-N CC(C)(C)OC(=O)NCC(C(O)=O)O[Si](C)(C)C(C)(C)C Chemical compound CC(C)(C)OC(=O)NCC(C(O)=O)O[Si](C)(C)C(C)(C)C BOVGQOZVWBFHBX-UHFFFAOYSA-N 0.000 description 2
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229940126062 Compound A Drugs 0.000 description 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000005215 alkyl ethers Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- PUJAMFCAXCENSX-XJDOXCRVSA-N benzyl (5S)-8-(phenylmethoxyamino)-6-azaspiro[2.5]octane-5-carboxylate Chemical compound O=C(OCc1ccccc1)[C@@H]1CC2(CC2)C(CN1)NOCc1ccccc1 PUJAMFCAXCENSX-XJDOXCRVSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940001468 citrate Drugs 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- QGRFCRJJRNGRSQ-UHFFFAOYSA-N ethyl 2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutylidene]acetate Chemical compound CCOC(=O)C=C1CC(NC(=O)OC(C)(C)C)C1 QGRFCRJJRNGRSQ-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- ZFSLODLOARCGLH-UHFFFAOYSA-N isocyanuric acid Natural products OC1=NC(O)=NC(O)=N1 ZFSLODLOARCGLH-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 235000014380 magnesium carbonate Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- RZHXOHMNXZKTRM-LBPRGKRZSA-N methyl (2S)-2-hydroxy-3-[2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoate Chemical compound C(C)(C)(C)OC(=O)N(C[C@@H](C(=O)OC)O)CCN(C)C(=O)OC(C)(C)C RZHXOHMNXZKTRM-LBPRGKRZSA-N 0.000 description 2
- HMJFYKPANPFQRX-VIFPVBQESA-N methyl (2S)-2-hydroxy-3-[2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]ethylamino]propanoate Chemical compound COC(=O)[C@@H](O)CNCCN(C)C(=O)OC(C)(C)C HMJFYKPANPFQRX-VIFPVBQESA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 2
- 229960001019 oxacillin Drugs 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
- JHLVEBNWCCKSGY-UHFFFAOYSA-N tert-butyl n-methylcarbamate Chemical compound CNC(=O)OC(C)(C)C JHLVEBNWCCKSGY-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003852 triazoles Chemical group 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- BOVGQOZVWBFHBX-SNVBAGLBSA-N (2R)-2-[tert-butyl(dimethyl)silyl]oxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C(C)(C)(C)OC(=O)NC[C@H](C(=O)O)O[Si](C)(C)C(C)(C)C BOVGQOZVWBFHBX-SNVBAGLBSA-N 0.000 description 1
- BOVGQOZVWBFHBX-JTQLQIEISA-N (2S)-2-[tert-butyl(dimethyl)silyl]oxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C(C)(C)(C)OC(=O)NC[C@@H](C(=O)O)O[Si](C)(C)C(C)(C)C BOVGQOZVWBFHBX-JTQLQIEISA-N 0.000 description 1
- DGAZDFILLMKTAT-UFYCRDLUSA-N (2S,5R)-2-[5-[(1S)-2-amino-1-[tert-butyl(dimethyl)silyl]oxyethyl]-1,3,4-oxadiazol-2-yl]-6-phenylmethoxyspiro[1,6-diazabicyclo[3.2.1]octane-4,1'-cyclopropane]-7-one Chemical compound NC[C@H](O[Si](C)(C)C(C)(C)C)C1=NN=C(O1)[C@@H]1CC2(CC2)[C@H]2N(C(N1C2)=O)OCC1=CC=CC=C1 DGAZDFILLMKTAT-UFYCRDLUSA-N 0.000 description 1
- JJCAYTVAYSGVLA-RXMQYKEDSA-N (2r)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC[C@@H](O)C(O)=O JJCAYTVAYSGVLA-RXMQYKEDSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UWTATZPHSA-N (2r)-3-azaniumyl-2-hydroxypropanoate Chemical compound [NH3+]C[C@@H](O)C([O-])=O BMYNFMYTOJXKLE-UWTATZPHSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- JJCAYTVAYSGVLA-YFKPBYRVSA-N (2s)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC[C@H](O)C(O)=O JJCAYTVAYSGVLA-YFKPBYRVSA-N 0.000 description 1
- FHOAKXBXYSJBGX-YFKPBYRVSA-N (2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)C(O)=O FHOAKXBXYSJBGX-YFKPBYRVSA-N 0.000 description 1
- YCDUQXXFNZLWJU-CROMWVBPSA-N (2s,5r,6r)-6-[[(2r)-2-(4-hydroxyphenyl)-2-[[6-oxo-2-(4-sulfamoylanilino)-1h-pyrimidin-5-yl]carbamoylamino]acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)NC(C(N1)=O)=CN=C1NC1=CC=C(S(N)(=O)=O)C=C1 YCDUQXXFNZLWJU-CROMWVBPSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- UQLCNZCWZPYVKS-BYPYZUCNSA-N (6S)-4-oxo-5-azaspiro[2.4]heptane-5,6-dicarboxylic acid Chemical compound O=C1N(C(O)=O)[C@H](C(=O)O)CC11CC1 UQLCNZCWZPYVKS-BYPYZUCNSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- PEZNEXFPRSOYPL-UHFFFAOYSA-N (bis(trifluoroacetoxy)iodo)benzene Chemical compound FC(F)(F)C(=O)OI(OC(=O)C(F)(F)F)C1=CC=CC=C1 PEZNEXFPRSOYPL-UHFFFAOYSA-N 0.000 description 1
- SQHSJJGGWYIFCD-UHFFFAOYSA-N (e)-1-diazonio-1-dimethoxyphosphorylprop-1-en-2-olate Chemical compound COP(=O)(OC)C(\[N+]#N)=C(\C)[O-] SQHSJJGGWYIFCD-UHFFFAOYSA-N 0.000 description 1
- BIUPYBKDMWIWJO-UHFFFAOYSA-N 1,1,1,3,3,3-hexachloropropan-2-one;triphenylphosphane Chemical compound ClC(Cl)(Cl)C(=O)C(Cl)(Cl)Cl.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 BIUPYBKDMWIWJO-UHFFFAOYSA-N 0.000 description 1
- FRXOYYBDUSFAGK-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane Chemical compound ClN1CN(Cl)CN(Cl)C1 FRXOYYBDUSFAGK-UHFFFAOYSA-N 0.000 description 1
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- BSIMZHVOQZIAOY-SCSAIBSYSA-N 1-carbapenem-3-carboxylic acid Chemical compound OC(=O)C1=CC[C@@H]2CC(=O)N12 BSIMZHVOQZIAOY-SCSAIBSYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PSQZJKGXDGNDFP-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropan-1-ol Chemical compound OCC(F)(F)C(F)(F)F PSQZJKGXDGNDFP-UHFFFAOYSA-N 0.000 description 1
- YOYAIZYFCNQIRF-UHFFFAOYSA-N 2,6-dichlorobenzonitrile Chemical compound ClC1=CC=CC(Cl)=C1C#N YOYAIZYFCNQIRF-UHFFFAOYSA-N 0.000 description 1
- CPORETJUHRURHL-UHFFFAOYSA-N 2-(but-3-ynylamino)ethanol Chemical compound OCCNCCC#C CPORETJUHRURHL-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- PRSYVZJLSVZHID-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]ethanethioic s-acid Chemical compound CC(C)(C)OC(=O)NCC(O)=S PRSYVZJLSVZHID-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- QGLVWTFUWVTDEQ-UHFFFAOYSA-N 2-chloro-3-methoxyphenol Chemical compound COC1=CC=CC(O)=C1Cl QGLVWTFUWVTDEQ-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- NXLASRNFOIGTBI-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propanethioic s-acid Chemical compound CC(C)(C)OC(=O)NCCC(S)=O NXLASRNFOIGTBI-UHFFFAOYSA-N 0.000 description 1
- WCFJUSRQHZPVKY-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCC(O)=O WCFJUSRQHZPVKY-UHFFFAOYSA-N 0.000 description 1
- KQIGMPWTAHJUMN-VKHMYHEASA-N 3-aminopropane-1,2-diol Chemical compound NC[C@H](O)CO KQIGMPWTAHJUMN-VKHMYHEASA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 1
- LIVTXZDKWJROLY-UHFFFAOYSA-N 3-morpholin-4-ylpropane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1.[O-]S(=O)(=O)CCC[NH+]1CCOCC1 LIVTXZDKWJROLY-UHFFFAOYSA-N 0.000 description 1
- CVYVXURBKURNKE-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound OC(=O)CCC(C)NC(=O)OC(C)(C)C CVYVXURBKURNKE-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- 101100248451 Arabidopsis thaliana RICE2 gene Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- VHOMAPWVLKRQAZ-UHFFFAOYSA-N Benzyl propionate Chemical compound CCC(=O)OCC1=CC=CC=C1 VHOMAPWVLKRQAZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005940 Bone and joint infections Diseases 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- RHMSVMDMWBZQNC-RQZCQDPDSA-N C(C1=CC=CC=C1)ON1C2CN(C(CC22CC2)/C=N/O)C1=O Chemical compound C(C1=CC=CC=C1)ON1C2CN(C(CC22CC2)/C=N/O)C1=O RHMSVMDMWBZQNC-RQZCQDPDSA-N 0.000 description 1
- UILOGRFWQXPRSG-GOTSBHOMSA-N CC(C)(C)OC(N(C1)CC1OCc1cc([C@H](CC2(CC2)[C@H](C2)N3OCc4ccccc4)N2C3=O)n[o]1)=O Chemical compound CC(C)(C)OC(N(C1)CC1OCc1cc([C@H](CC2(CC2)[C@H](C2)N3OCc4ccccc4)N2C3=O)n[o]1)=O UILOGRFWQXPRSG-GOTSBHOMSA-N 0.000 description 1
- RSAHOMRSRWAPAF-UHFFFAOYSA-N CC(C1)CN1C(OC(C)(C)C)=O Chemical compound CC(C1)CN1C(OC(C)(C)C)=O RSAHOMRSRWAPAF-UHFFFAOYSA-N 0.000 description 1
- UPTCETPXMJZUNH-UHFFFAOYSA-N CCC(CC=C)NCC([O](C)CC)=O Chemical compound CCC(CC=C)NCC([O](C)CC)=O UPTCETPXMJZUNH-UHFFFAOYSA-N 0.000 description 1
- WOGADGJSAJAAEH-UHFFFAOYSA-N CCC(CCC=C)N(CC(OCC)=O)C(OC(C)(C)C)=O Chemical compound CCC(CCC=C)N(CC(OCC)=O)C(OC(C)(C)C)=O WOGADGJSAJAAEH-UHFFFAOYSA-N 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000872931 Myoporum sandwicense Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 1
- UQFQONCQIQEYPJ-UHFFFAOYSA-N N-methylpyrazole Chemical compound CN1C=CC=N1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 1
- WXNAJNXODCAPEV-HALWSDQMSA-N O/N=C(/[C@H](CC1(CC1)[C@H](C1)N2OC3=CC=CC=C3)N1C2=O)\Cl Chemical compound O/N=C(/[C@H](CC1(CC1)[C@H](C1)N2OC3=CC=CC=C3)N1C2=O)\Cl WXNAJNXODCAPEV-HALWSDQMSA-N 0.000 description 1
- PBJPTORMUUUTBG-IBGZPJMESA-N O=C([C@H](CC12CC1)NCC2=[NH+][O-]Cc1ccccc1)OCc1ccccc1 Chemical compound O=C([C@H](CC12CC1)NCC2=[NH+][O-]Cc1ccccc1)OCc1ccccc1 PBJPTORMUUUTBG-IBGZPJMESA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- SMOBCLHAZXOKDQ-ZJUUUORDSA-N [(2s,5r)-7-oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate Chemical compound O=C([C@H]1N2C[C@@](CC1)(N(C2=O)OS(O)(=O)=O)[H])NC1CCNCC1 SMOBCLHAZXOKDQ-ZJUUUORDSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- QPQGTZMAQRXCJW-UHFFFAOYSA-N [chloro(phenyl)phosphoryl]benzene Chemical compound C=1C=CC=CC=1P(=O)(Cl)C1=CC=CC=C1 QPQGTZMAQRXCJW-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- DNSIJEBVUGVVIO-IBGZPJMESA-N benzyl (5S)-8-phenylmethoxyimino-6-azaspiro[2.5]octane-5-carboxylate Chemical compound O=C(OCc1ccccc1)[C@@H]1CC2(CC2)C(CN1)=NOCc1ccccc1 DNSIJEBVUGVVIO-IBGZPJMESA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000003460 beta-lactamyl group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- PQEPCBUBKRUREA-UHFFFAOYSA-N but-3-ynylazanium;chloride Chemical compound Cl.NCCC#C PQEPCBUBKRUREA-UHFFFAOYSA-N 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000014670 detection of bacterium Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- AWXZEGZGFQCFMS-UHFFFAOYSA-N ethyl 2-[3-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutyl]acetate Chemical compound CCOC(=O)CC1CC(NC(=O)OC(C)(C)C)C1 AWXZEGZGFQCFMS-UHFFFAOYSA-N 0.000 description 1
- IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- DWYMPOCYEZONEA-UHFFFAOYSA-L fluoridophosphate Chemical compound [O-]P([O-])(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-L 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- DQDCGTUHSVXZIS-UHFFFAOYSA-N iodobenzene;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F.IC1=CC=CC=C1 DQDCGTUHSVXZIS-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- LFVPHXOOLUCFFB-VKHMYHEASA-N methyl (2s)-3-amino-2-hydroxypropanoate Chemical compound COC(=O)[C@@H](O)CN LFVPHXOOLUCFFB-VKHMYHEASA-N 0.000 description 1
- CBSWQPBHPCWSAX-UHFFFAOYSA-N methyl 3-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound COC(=O)CC(C)CNC(=O)OC(C)(C)C CBSWQPBHPCWSAX-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 229950010703 piroxicillin Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229950011310 relebactam Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- PANBYUAFMMOFOV-UHFFFAOYSA-N sodium;sulfuric acid Chemical compound [Na].OS(O)(=O)=O PANBYUAFMMOFOV-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 1
- 229960003865 tazobactam Drugs 0.000 description 1
- LCZVKKUAUWQDPX-UHFFFAOYSA-N tert-butyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]ethyl]amino]acetate Chemical compound CC(=O)OC1=CC=CC=C1CN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC1=CC=CC=C1OC(C)=O LCZVKKUAUWQDPX-UHFFFAOYSA-N 0.000 description 1
- LIUMYBWTRZTNMS-UHFFFAOYSA-N tert-butyl 2-bromo-2,2-difluoroacetate Chemical compound CC(C)(C)OC(=O)C(F)(F)Br LIUMYBWTRZTNMS-UHFFFAOYSA-N 0.000 description 1
- JWHFSDTYDAIZID-UHFFFAOYSA-N tert-butyl 3-(2-oxoethyl)azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(CC=O)C1 JWHFSDTYDAIZID-UHFFFAOYSA-N 0.000 description 1
- XMNFVBVPPKGBOZ-UHFFFAOYSA-N tert-butyl 4-(but-3-ynylamino)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(NCCC#C)CC1 XMNFVBVPPKGBOZ-UHFFFAOYSA-N 0.000 description 1
- HNQPIMSHTUPWIT-UHFFFAOYSA-N tert-butyl 4-[but-3-ynyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N(CCC#C)C1CCN(C(=O)OC(C)(C)C)CC1 HNQPIMSHTUPWIT-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- UMWLAZLRXGEEDZ-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)-n-but-3-ynylcarbamate Chemical compound CC(C)(C)OC(=O)N(CCN)CCC#C UMWLAZLRXGEEDZ-UHFFFAOYSA-N 0.000 description 1
- FNHPTFKSPUTESA-UHFFFAOYSA-N tert-butyl n-(3-oxocyclobutyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CC(=O)C1 FNHPTFKSPUTESA-UHFFFAOYSA-N 0.000 description 1
- ZBUIOQQRBIZZOM-UHFFFAOYSA-N tert-butyl n-[2-(1,3-dioxoisoindol-2-yl)ethyl]carbamate Chemical compound C1=CC=C2C(=O)N(CCNC(=O)OC(C)(C)C)C(=O)C2=C1 ZBUIOQQRBIZZOM-UHFFFAOYSA-N 0.000 description 1
- QFNFDHNZVTWZED-UHFFFAOYSA-N tert-butyl n-[[(2-methylpropan-2-yl)oxycarbonylamino]-pyrazol-1-ylmethylidene]carbamate Chemical compound CC(C)(C)OC(=O)NC(=NC(=O)OC(C)(C)C)N1C=CC=N1 QFNFDHNZVTWZED-UHFFFAOYSA-N 0.000 description 1
- CMYCTEJHMUTVCB-UHFFFAOYSA-N tert-butyl n-but-3-enyl-n-(2-hydroxyethyl)carbamate Chemical compound CC(C)(C)OC(=O)N(CCO)CCC=C CMYCTEJHMUTVCB-UHFFFAOYSA-N 0.000 description 1
- ISTGQSQWSKCNFJ-UHFFFAOYSA-N tert-butyl n-ethylcarbamate Chemical compound CCNC(=O)OC(C)(C)C ISTGQSQWSKCNFJ-UHFFFAOYSA-N 0.000 description 1
- MSWTVSDFEYSRMQ-UHFFFAOYSA-N tert-butyl n-methyl-n-(2-oxoethyl)carbamate Chemical compound O=CCN(C)C(=O)OC(C)(C)C MSWTVSDFEYSRMQ-UHFFFAOYSA-N 0.000 description 1
- QVMLIHFGUIRVKU-UHFFFAOYSA-N tert-butyl n-methyl-n-prop-2-ynylcarbamate Chemical compound C#CCN(C)C(=O)OC(C)(C)C QVMLIHFGUIRVKU-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Definitions
- the present invention relates to a beta-lactamase inhibitor and a process for the preparation thereof.
- the invention further relates to a pharmaceutical composition comprising a beta-lactamase inhibitor and to the use thereof.
- Beta-lactam antibiotics are the first antibiotics cited in the clinic. Since the successful application of penicillin G as the first ⁇ -lactam antibiotic to the clinic, ⁇ -lactam antibiotics have developed rapidly. Different structure types of ⁇ -lactam antibiotics have been developed and applied in a large number of clinical applications, and have achieved good results. However, since bacterial cells can produce ⁇ -lactamase, the antibiotics are inactivated, causing the bacteria to develop resistance to ⁇ -lactam antibiotics.
- the ⁇ -lactamase is an enzyme that catalyzes the hydrolysis of the ⁇ -lactam ring, which inactivates the antibacterial activity of the ⁇ -lactam antibiotic and allows the bacteria to be resistant to the ⁇ -lactam antibiotic.
- the ⁇ -lactamase can be classified into A, B, C, and D depending on the amino acid sequence difference in the molecular structure.
- Class A ⁇ -lactamases preferably hydrolyze penicillin antibiotics
- Class B ⁇ -lactamases can hydrolyze various ⁇ -lactam antibiotics, including carbapenems
- Class C ⁇ -lactamases are more effective.
- Hydrolyzed cephalosporin antibiotics while D-type ⁇ -lactamases are more prone to hydrolyzing oxacillin and o-chloropenicillin.
- the resistance of bacteria, especially Gram-negative bacteria, to ⁇ -lactam antibiotics is usually mediated by ⁇ -lactamase.
- Inhibition of ⁇ -lactamase can delay or inhibit the degradation of ⁇ -lactam antibiotics and restore the sensitivity of bacteria producing ⁇ -lactam antibiotic resistance to ⁇ -lactam antibiotics.
- ⁇ -lactamase can inactivate the hydrolysis activity of ⁇ -lactam antibiotics, thereby enhancing the bacteria against ⁇ -lactam.
- the sensitivity of antibiotics reduces or overcomes the problem of drug resistance.
- bacteriostatic beta-lactamase inhibitors such as those disclosed in WO2013149121A1, WO2014141132A1, US20130296290A1, WO2013030735A1, WO2015110963A1, WO2015150890A1, WO2015159265A1, WO2015173663, WO2015173665A1, WO2017055922A1 [bicyclo[3.2.1] ] Octane compounds.
- beta-lactamase inhibitors available on the market, such as clavulanic acid, tazobactam, abivudan, Relebactam, and the like.
- the present invention provides a compound of the formula (I) or an ester thereof, a stereoisomer thereof, and a pharmaceutically acceptable salt thereof:
- W 1 is selected from the group consisting of an optionally substituted five- or six-membered heteroaryl ring containing O, N and/or S or -C(O)-; and, (i) when W 1 is selected from the group consisting of optionally substituted When a 5- or 6-membered heteroaryl ring of O, N and/or S is substituted, W 1 is optionally substituted by C 1 -C 12 alkyl,
- W 2 is selected from:
- R 1 is selected from Wherein R 2 , R 3 , R 4 , R 4 ', R 5 or R 6 are each independently selected from H, C 1 -C 12 alkyl, amino C 1 -C 12 alkyl, C 1 -C 12 alkylamine Base C 1 -C 12 alkyl, Ra and Rb are each independently selected from H, C 1 -C 12 alkyl, OH, -OC 1 -C 12 alkyl, -NH 2 , -NHC 1 -C 12 alkyl, -N(C 1 -C 12 Alkyl) 2 , -SH, -SC 1 -C 12 alkyl, -S(O)C 1 -C 12 alkyl, -S(O 2 )C 1 -C 12 alkyl, -SO 3 H;R 7 and R 7 ' are each independently selected from -NH 2 , -NHC 1 -C 12 alkyl, -N(C 1 -C 12 alkyl
- R 1 ' is selected from H, C 1 -C 12 alkyl, C 3 -C 8 cycloalkyl, OH, -OC 1 -C 12 alkyl, -NH 2 , -NHC 1 -C 12 alkyl, -N (C 1 -C 12 alkyl) 2 , -SH, -SC 1 -C 12 alkyl, -S(O)C 1 -C 12 alkyl, -S(O 2 )C 1 -C 12 alkyl, -SO 3 H;
- Z 2 is selected from CR 18 R 19 or NR 20 , and R 18 , R 19 and R 20 are each independently selected from H, NH 2 or
- R 21 is selected from the group consisting of -NH 2 , -NHC 1 -C 12 alkyl, -N(C 1 -C 12 alkyl) 2 , -O C 1 -C 12 alkyl, -S C 1 -C 12 alkyl;
- R 22 is selected from the group consisting of NH, -NHC 1 -C 12 alkyl, O, S;
- t, u and w are each independently selected from 1, 2, 3, 4, 5 or 6, provided that t and u are not 0 at the same time;
- W 1 when W 1 is selected from -C(O)-, W 2 is selected from -OR 26 , -NHR 27 , wherein R 26 and R 27 are each independently selected from H, C 1 -C 12 alkyl or Wherein Z 5 is selected from CR 28 R 29 or NR 30 , and R 28 , R 29 and R 30 are each independently selected from H, NH 2 or Wherein R 31 is selected from the group consisting of -NH 2 , -NHC 1 -C 12 alkyl, -N(C 1 -C 12 alkyl) 2 , -O C 1 -C 12 alkyl, -S C 1 -C 12 alkyl; R 32 is selected from the group consisting of NH, NC 1 -C 12 alkyl, O, S; x, y and z are each independently selected from 1, 2, 3, 4, 5 or 6, provided that x and y are not simultaneously 0;
- W 3 is selected from the group consisting of -SO 3 M, -OSO 3 M, -OSO 2 NH 2 , -OPO 3 M, -OCR 33 R 34 CO 2 M, -OCR 35 R 36 SO 3 M, -OCR 37 R 38 PO 3 M; wherein M is selected from H or a pharmaceutically acceptable cation; and R 33 , R 34 , R 35 , R 36 , R 37 and R 38 are each independently selected from H, C 1 -C 12 alkyl, halogen.
- the present invention provides a process for the preparation of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof and one or more ⁇ -lactam antibiotics.
- the present invention provides a method of treating a disease caused by a bacterial infection comprising administering a compound of the formula (I) as described herein in combination with one or more ⁇ -lactam antibiotics A patient or subject in need.
- alkyl refers to a straight or branched saturated hydrocarbon group having from 1 to 20 carbon atoms.
- the alkyl group is an alkyl group having from 1 to 12 carbon atoms. More preferably, the alkyl group is an alkyl group having 1 to 6 carbon atoms. Most preferably, the alkyl group is an alkyl group having from 1 to 4 carbon atoms.
- alkyl groups include, but are not limited to, methyl, ethyl, 1-propyl (n-propyl), 2-propyl (isopropyl), 1-butyl (n-butyl), 2-methyl 1-propyl (isobutyl), 2-butyl (sec-butyl), 2-methyl-2-propyl (tert-butyl), 1-pentyl (n-pentyl), 2-pentyl , 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2- Methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, 1-heptyl, 1-octyl
- amino refers to -NH 2.
- halogen refers to fluoro, chloro, bromo, iodo.
- aminoalkyl refers to an alkyl group in which one or more hydrogens are replaced by an amino group.
- cycloalkyl refers to a monovalent saturated carbocyclic group.
- the cycloalkyl group is a 3 to 8 membered monocyclic group. More preferably, the cycloalkyl group is a 3- to 6-membered monocyclic group.
- Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- heteroaryl refers to a 5- or 6-membered, monovalent aromatic radical containing 1-3 heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur.
- heteroaryl groups include: furan ring, pyrrole ring, pyrazole ring, imidazole ring, triazole ring, thiophene ring, thiazole ring, isothiazole ring, oxazole ring, isoxazole ring, 1,2,4-oxine Diazole ring, 1,3,4-oxadiazole ring; pyridine ring, pyrimidinyl group, triazine ring, pyrazine ring, tetrazole ring, pyridazine ring, thiadiazole ring.
- the heteroaryl group is optionally substituted independently with one or more substituents as described herein.
- the term "optionally substituted” means that the given structure or group is unsubstituted or that the given structure or group is substituted with one or more specific substituents. Unless otherwise stated, the optional substitution can be substituted at any position of the substituted group.
- ester refers to an ester of -OSO 3 - or COOH (if present) in the compound of formula (I) which can be esterified with an alcohol; as shown in formula (I) When a hydroxyl group is present in the compound, it can be esterified with an organic acid, an inorganic acid or the like to form an ester. The ester can be hydrolyzed under acidic or basic conditions to form the corresponding acid or alcohol.
- stereoisomer refers to a compound that has the same chemical composition and connectivity, but whose atoms have different orientations in space, which orientation cannot be interchanged by single bond rotation.
- Stepoisomers include “diastereomers” and “enantiomers.”
- Diastereomer refers to a stereoisomer that has two or more centers of chirality and whose molecules are not mirror images of each other. Diastereomers have different physical properties such as melting point, boiling point, spectral properties and reactivity. The mixture of diastereomers can be separated under high resolution analytical procedures such as crystallization, electrophoresis and chromatography.
- Enantiomer refers to two stereoisomers that are non-overlapping mirror images of each other.
- salts refers to a pharmaceutically acceptable organic or inorganic salt of a compound of the invention.
- exemplary salts include, but are not limited to, sulfates, citrates, acetates, oxalates, chlorides, bromides, iodides, nitrates, hydrogen sulfates, phosphates, acid phosphates, isoniazids Acid salt, lactate, salicylate, acid citrate, tartrate, oleate, citrate, pantothenate, hydrogen tartrate, ascorbate, succinate, maleate, dragon Cholate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate (methanesulfonate), B Alkane sulfonate, besylate, p-toluenesulfonate, and pamoate; or ammonium (eg, primary
- the term "pharmaceutically acceptable” means that the substance or composition must be chemically and/or toxicologically compatible with the other ingredients of the mammal comprising the formulation and/or treatment therewith.
- treatment refers to both therapeutic and prophylactic or preventative or preventive measures, wherein the goal is to prevent or slow (reduce) undesired pathological changes or conditions.
- beneficial or desirable clinical outcomes include, but are not limited to, alleviation of symptoms, reduction in disease severity, delay or slowing of disease progression, improvement or mitigation of disease states, and relief (either in part or in whole), regardless of Is detectable or undetectable.
- the term "therapeutically effective amount” means that the amount of a compound of the invention may be: (i) treating or preventing a disease or condition described herein, (ii) ameliorating or eliminating one or more diseases or conditions described herein. Or (iii) preventing or delaying the onset of one or more symptoms of the disease or condition described herein.
- the invention claims a compound of formula (Ia) or an ester, solvate, stereoisomer thereof, and pharmaceutically acceptable salts thereof:
- W 1 , W 2 and W 3 are as defined in the formula (I).
- W 1 is selected from the group consisting of an optionally substituted five- or six-membered heteroaryl ring containing O, N and/or S;
- W 2 is selected from:
- R 1 is selected from Wherein R 2 , R 3 , R 4 , R 4 ', R 5 or R 6 are each independently selected from H, C 1 -C 12 alkyl, amino C 1 -C 12 alkyl, C 1 -C 12 alkylamine Base C 1 -C 12 alkyl, Ra and Rb are each independently selected from H, C 1 -C 12 alkyl, OH, -OC 1 -C 12 alkyl, -NH 2 , -NHC 1 -C 12 alkyl, -N(C 1 -C 12 Alkyl) 2 , -SH, -SC 1 -C 12 alkyl, -S(O)C 1 -C 12 alkyl, -S(O 2 )C 1 -C 12 alkyl, -SO 3 H;R 7 and R 7 ' are each independently selected from -NH 2 , -NHC 1 -C 12 alkyl, -N(C 1 -C 12 alkyl
- R 1 ' is selected from H, C 1 -C 12 alkyl, C 3 -C 8 cycloalkyl, OH, -OC 1 -C 12 alkyl, -NH 2 , -NHC 1 -C 12 alkyl, -N (C 1 -C 12 alkyl) 2 , -SH, -SC 1 -C 12 alkyl, -S(O)C 1 -C 12 alkyl, -S(O 2 )C 1 -C 12 alkyl, -SO 3 H;
- Z 2 is selected from CR 18 R 19 or NR 20 , and R 18 , R 19 and R 20 are each independently selected from H, NH 2 or
- R 21 is selected from the group consisting of -NH 2 , -NHC 1 -C 12 alkyl, -N(C 1 -C 12 alkyl) 2 , -O C 1 -C 12 alkyl, -S C 1 -C 12 alkyl;
- R 22 is selected from the group consisting of NH, -NHC 1 -C 12 alkyl, O, S;
- t, u and w are each independently selected from 1, 2, 3, 4, 5 or 6, provided that t and u are not 0 at the same time;
- Or NH;
- R 25 is selected from H, amino C 1 -C 12 alkyl or C 1 -C 12 alkylamino C 1 -C 12 alkyl.
- W 1 is selected from Wherein X is selected from O, S or NH, and Y and Z are each independently selected from CH or N, and W 1 is optionally substituted by C 1 -C 12 alkyl.
- W 1 is selected from the group consisting of a furan ring, a pyrrole ring, a pyrazole ring, an imidazole ring, a triazole ring, a thiophene ring, a thiazole ring, an isothiazole ring, an oxazole ring, an isoxazole ring, 1,2,4- Oxadiazole ring, 1,3,4-oxadiazole ring; pyridine ring, pyrimidinyl group, triazine ring, pyrazine ring, tetrazole ring, pyridazine ring, thiadiazole ring.
- W 1 is selected from the group consisting of
- M is selected from the group consisting of H, sodium ion, potassium ion, calcium ion, magnesium ion, NH 4 + , N(C 1 -C 12 alkyl) 4 + .
- W 1 is selected from the group consisting of -C(O)-;
- W 2 is selected from the group consisting of -OR 26 , -NHR 27 , wherein R 26 and R 27 are each independently selected from H, C 1 -C 12 alkyl or Wherein Z 5 is selected from CR 28 R 29 or NR 30 , and R 28 , R 29 and R 30 are each independently selected from H, NH 2 or Wherein R 31 is selected from the group consisting of -NH 2 , -NHC 1 -C 12 alkyl, -N(C 1 -C 12 alkyl) 2 , -O C 1 -C 12 alkyl, -S C 1 -C 12 alkyl; R 32 is selected from the group consisting of NH, NC 1 -C 12 alkyl, O, S; x, y and z are each independently selected from 1, 2, 3, 4, 5 or 6, provided that x and y are not simultaneously 0.
- Preferred compounds of the invention are as follows:
- the invention provides a process for the preparation of a compound of formula (I) of the invention:
- Step 1 The intermediate 1 is reacted with an alkyne under basic conditions to obtain an intermediate 2;
- Step 2 Selective removal of the intermediate 2 to the protecting group P to obtain the intermediate 3;
- Step 3 Intermediate 3 is reacted with SO 3 under basic conditions to obtain Intermediate 4;
- Step 4 The protecting group P' in the intermediate 4 is removed to give the product 5.
- P is a hydroxy protecting group which is common in the art
- P' is a hydroxy or amino protecting group which is common in the art
- B is as defined in the formula (I).
- Hydroxy or amino protecting groups include, but are not limited to, benzyl, silane protecting groups, ester protecting groups, alkyl ether protecting groups, Boc, Fmoc, Cbz, etc. See, for example, Greene, TW and Wuts, PGM, Greene's Protective Groups in Organic Synthesis, 4th edition, John Wiley and Sons.
- the base used in the reaction may be an inorganic base or an organic base, wherein the inorganic base may be selected from alkali metal or alkaline earth metal hydroxides (for example, sodium hydroxide, potassium hydroxide, barium hydroxide, lithium hydroxide).
- alkali metal or alkaline earth metal hydroxides for example, sodium hydroxide, potassium hydroxide, barium hydroxide, lithium hydroxide.
- alkali metal or alkaline earth metal carbonate or hydrogencarbonate such as potassium carbonate, sodium carbonate, lithium carbonate, calcium carbonate, magnesium carbonate, sodium hydrogencarbonate
- alkali metal or alkaline earth metal Alkoxide such as sodium methoxide, sodium ethoxide, sodium t-butoxide, potassium t-butoxide, etc.
- alkali metal or alkaline earth metal amide such as sodium amide, sodium hexamethyldisilazide
- ammonia organic base can Selected from organic amines commonly found in the art, such as triethylamine, trimethylamine, pyridine, piperidine, 4-N,N-dimethylaminopyridine, morpholine, N-methylmorpholine, tetramethylethylenediamine , DBU, DBN, DABCO, etc.
- the deprotection operation is a routine experimental operation in the art, see, for example, Greene, T. W. and Wuts, P. G. M., Greene's Protective Groups in Organic Synthesis, 4th edition, John Wiley and Sons.
- step 3 the base used in the reaction is as defined in step 1.
- P is a hydroxy protecting group which is common in the art
- P' is a hydroxy or amino protecting group which is common in the art
- B is as defined in the formula (I).
- Hydroxy or amino protecting groups include, but are not limited to, benzyl, silane protecting groups, ester protecting groups, alkyl ether protecting groups, Boc, Fmoc, Cbz, etc. See, for example, Greene, TW and Wuts, PGM, Greene's Protective Groups in Organic Synthesis, 4th edition, John Wiley and Sons.
- Step 1 Intermediate 1 is condensed with a hydrazide under basic conditions to obtain Intermediate 2; wherein the base used in the reaction may be an inorganic base or an organic base, which is defined as the base in step 1 of Scheme 1.
- the condensing agent may be a condensing agent commonly used in the art for the condensation reaction between a carboxylic acid and an amine, such as a carbodiimide condensing agent (CDI, DCC, DIC, EDCI and DMAP, HOBt, HOAt, HOSu, NHPI).
- the reaction temperature may be in the range of 0-100 ° C, preferably in The reaction is in the range of 0-70 ° C, more preferably 0-50 ° C, most preferably at room temperature.
- Step 2 Intermediate 2 is obtained by a ring closure reaction to obtain Intermediate 3; wherein the ring closure reaction is carried out in the presence of a condensing agent, and the condensing agent used is preferably Burgess reagent; the reaction temperature may be in the range of 0-100 ° C, It is preferably in the range of 0 to 70 ° C, more preferably 0 to 50 ° C, most preferably at room temperature.
- a condensing agent preferably Burgess reagent
- the reaction temperature may be in the range of 0-100 ° C, It is preferably in the range of 0 to 70 ° C, more preferably 0 to 50 ° C, most preferably at room temperature.
- Step 3 Selective removal of the intermediate 3 to the protecting group P to obtain the intermediate 4;
- Step 4 Intermediate 4 is reacted with SO 3 under basic conditions to obtain Intermediate 5;
- Step 5 removing the protecting group P' in the intermediate 5 to obtain the product 6;
- the deprotection operation is a routine experimental operation in the art, see, for example, Greene, T. W. and Wuts, P. G. M., Greene's Protective Groups in Organic Synthesis, 4th edition, John Wiley and Sons.
- step 4 the base used in the reaction is as defined in step 1 of Scheme 1.
- the present invention provides a pharmaceutical composition of the compound of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- the composition comprises a compound of the invention, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier can be either solid or liquid. Wherein the solid carrier can be one or more of those used as excipients, diluents, sweeteners, solubilizers, lubricants, binders, tablet disintegrating agents, stabilizers, preservatives or encapsulating materials. substance.
- the liquid carrier can be a solvent or a liquid dispersion medium.
- Suitable solid carriers include, but are not limited to, for example, cellulose, glucose, lactose, mannitol, magnesium stearate, magnesium carbonate, sodium carbonate, sodium saccharin, sucrose, dextrin, talc, starch, pectin, gelatin, tragacanth, Acacia gum, sodium alginate, parabens, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
- Suitable liquid carriers include, but are not limited to, water, ethanol, polyols (eg, glycerol, propylene glycol, liquid polyethylene glycol, and the like), vegetable oils (eg, peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil). ), glycerides, agar, pyrogen-free water, isotonic saline, Ringer's solution, and mixtures thereof.
- polyols eg, glycerol, propylene glycol, liquid polyethylene glycol, and the like
- vegetable oils eg, peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil.
- glycerides eg, agar, pyrogen-free water, isotonic saline, Ringer's solution, and mixtures thereof.
- compositions of the invention are generally known.
- the preparation of the pharmaceutical compositions of the present invention in a known manner includes conventional methods of mixing, granulating, tableting, coating, dissolving or lyophilizing.
- the therapeutically effective amount of the compound of the present invention or a pharmaceutical composition comprising the same can be easily determined by routine experimentation, and the most effective and convenient route of administration can be determined by routine experimentation.
- the pharmaceutical composition of the present invention can be administered to a patient or a subject in need of treatment by any suitable administration, including oral administration, parenteral (including subcutaneous, intramuscular, intravenous, and intradermal) administration.
- parenteral including subcutaneous, intramuscular, intravenous, and intradermal
- Inhalation spray administration topical administration, rectal administration, nasal administration, buccal administration, vaginal administration or administration via an implantable reservoir.
- the provided pharmaceutical compositions are administered intravenously and/or intraperitoneally.
- parenteral includes subcutaneous, intravenous, intramuscular, intraocular, intravitreal, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic. , intraperitoneal, intralesional, and intracranial injection or infusion techniques.
- these pharmaceutical compositions are administered orally, subcutaneously, intraperitoneally or intravenously. .
- compositions suitable for oral administration for use in the present invention include solid forms such as pills, tablets, caplets, capsules (including immediate release formulations, time release formulations and sustained release formulations, respectively), granules and powders; and liquids Forms such as solutions, syrups, elixirs, emulsions and suspensions.
- forms for ocular administration include sterile solutions or ocular delivery devices.
- Forms useful for parenteral administration include sterile solutions, emulsions and suspensions.
- the pharmaceutical composition of the present invention may additionally comprise one or more ⁇ -lactam antibiotics.
- the ⁇ -lactam antibiotic may include a penicillin antibiotic, a cephalosporin antibiotic, a monolactam cyclic antibiotic, a carbapenem antibiotic, and a penemase inhibitor.
- the ⁇ -lactam antibiotic may include penicillin, oxacillin, cloxacillin, dicloxacillin, flucloxacillin, ampicillin, piroxicillin, amoxicillin, carbenicillin, furazocillin, sulfonate.
- a compound of the present invention or an ester thereof, a stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound of the present invention or an ester thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, can be used for treatment and / or prevent diseases caused by bacterial infections. Therefore, in the use of the compound of the formula (I) of the present invention, an ester thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment and/or prevention of bacteria The disease caused by infection.
- the present invention relates to a method of inhibiting bacteria or treating and/or preventing a disease caused by a bacterial infection, comprising administering to a patient or subject in need thereof a therapeutically and/or prophylactically effective amount of the formula (I) of the present invention.
- the bacteria in the disease caused by bacterial interference are selected from the group consisting of Gram-positive bacteria and Gram-negative bacteria, wherein the Gram-positive bacteria are selected from the group consisting of: Staphylococcus aureus, Staphylococcus epidermidis, and lactose-free chains One or more of cocci, S. pneumoniae, Streptococcus pyogenes, Enterococcus or C.
- Gram-negative bacteria selected from the group consisting of: Citrobacter faecalis, Citrobacter freundii, Enterobacter cloacae, pneumonia Lei Bojun, Escherichia coli, Proteus vulgaris, Salmonella, Serratia marcescens, Shigella, Pseudomonas aeruginosa, Moraxella muforma, Neisseria gonorrhoeae, Neisseria meningitidis, immobile Bacillus, Burkholder, Campylobacter, Helicobacter pylori, Vibrio cholerae, Klebsiella, Haemophilus influenzae, Mycobacterium avium, Mycobacterium abscessus, Mycobacterium kansii, Mycobacterium ulcerum, Chlamydia pneumoniae, Trachoma One or more of Chlamydia, ⁇ -hemolytic streptococcus, Acinetobacter baumannii,
- the bacterium causes a disease selected from the group consisting of: respiratory tract infection (upper respiratory tract infection, lower respiratory tract infection, bronchitis, bronchitis, pneumonia, tuberculosis, pharyngitis), urinary tract infection (complex urinary tract infection, complicated urethra) Infection, non-concurrent urinary tract infection, cystitis, pyelonephritis), central nervous system infection (encephalitis, meningitis, brain abscess), ear infection (otitis, otitis media), pleural lung and bronchial infection, intra-abdominal infection , cardiovascular infection (blood infections such as sepsis or bacteremia, endocarditis, myocarditis, pericarditis), skin or soft tissue infections, bone and joint infections (arthritis, osteomyelitis), genital infections (genital ulcers, vaginitis) , cervicitis), one or more of eye infections (conjunctivitis,
- the compounds or pharmaceutical compositions of the invention may be provided in a pack or dispenser device containing one or more unit dosage forms.
- the package may comprise a metal or plastic foil or glass and a rubber stopper (eg, in a vial).
- the package or dispensing device can be accompanied by a instructions for use of the drug.
- the dosage will depend on various factors including the age, weight and condition of the patient as well as the route of administration. The precise dose administered is determined based on the judgment of the treating physician.
- the actual dosage level and time course of administration of the active ingredient in the pharmaceutical compositions of the present invention can be varied to achieve the following amounts of active ingredient which are effective to achieve the desired condition for the particular patient, composition and mode of administration.
- the response is treated without toxicity to the patient.
- the agents or pharmaceutical compositions of the invention are administered in an amount sufficient to reduce or eliminate the symptoms associated with bacterial infection.
- the preferred dosage of the agent is the maximum amount that the patient can withstand and does not produce serious or unacceptable side effects.
- Exemplary dosage ranges include 0.01 mg to 250 mg/day, 0.01 mg to 100 mg/day, 1 mg to 100 mg/day, 10 mg to 100 mg/day, 1 mg to 10 mg/day, and 0.01 mg to 10 mg/day.
- the preferred dosage of the agent is the maximum amount that the patient can withstand and does not produce serious or unacceptable side effects.
- the agent is administered at a concentration of from about 10 micrograms to about 100 mg/kg body weight per day, from about 0.1 to about 10 mg/kg/day, or from about 1.0 mg to about 10 mg/kg body weight per day.
- the therapeutically effective dose produces a serum concentration of the agent from about 0.1 ng/ml to about 50-100 mg/ml.
- These pharmaceutical compositions should typically provide a dosage of from about 0.001 mg to about 2000 mg of compound per kilogram of body weight per day.
- the dose for systemic administration to a human patient may range from 1-10 mg/kg, 20-80 mg/kg, 5-50 mg/kg, 75-150 mg/kg, 100-500 mg/kg, 250-750 mg/kg.
- the pharmaceutical unit dosage form is prepared to provide a compound or combination of essential ingredients from about 1 mg to about 5000 mg (e.g., from about 100 mg to about 2500 mg) per unit dosage form.
- Preferred unit dosage formulations are those containing the daily dose or unit, daily sub-dose, or suitable fraction thereof as discussed herein.
- Steps 1-4 follow steps 2-5 in the synthesis of Compound D.
- Step 1-6 Steps 1-6 in the synthesis of Compound D
- Step 1-6 Steps 1-6 in the synthesis of Compound E
- the crude product was purified by Prep-HPLC using the following conditions: column: XBridge Prep OBD C18 column 19*250 mm, 5 um; mobile phase A: water (0.1% FA), mobile phase B: ACN; flow rate: 20 mL/min; gradient: From 12% B to 23% B in 7 minutes; 220, 254 nm; Rt: 6.2 min; 8 mg (12%) of compound E was obtained.
- ESI-MS (EI + , m/z): 402, 0.418 min.
- Step 1-6 Steps 1-6 in the synthesis of Compound D
- Step 1-6 Steps 1-6 in the synthesis of Compound D
- Step 1-5 follow steps 1-6 in the synthesis of Compound I
- Step 6 follow step 8 in the synthesis of Compound I
- Step 7-8 follow steps 1-2 in the synthesis of Compound E
- ESI-MS EI + , m/z
- Steps 10-12 Steps 3-5 in the synthesis of Compound E
- Step 1-6 Steps 1-6 in the synthesis of Compound E
- Step 1-6 Steps 1-6 in the synthesis of Compound E
- Step 1-6 Steps 1-6 in the synthesis of Compound E
- Step 1-3 follow steps 1-3 in the synthesis of Compound D
- Step 4-8 Steps 1-5 in the synthesis of Compound E
- Step 3-8 Steps 1-6 in the synthesis of Compound D
- Step 1-6 Steps 1-6 in the synthesis of Compound D
- Step 1-6 Steps 1-6 in the synthesis of Compound D
- Step 1-6 Steps 1-6 in the synthesis of Compound D
- Step 1-6 Steps 1-6 in the synthesis of Compound D
- Step 3-8 Steps 1-6 in the synthesis of Compound D
- Step 1-3 follow steps 4-6 in the synthesis of Compound D
- Step 1-6 Steps 1-6 in the synthesis of Compound D
- Step 1-6 Steps 1-6 in the synthesis of Compound D
- Step 1-6 Steps 1-6 in the synthesis of Compound D
- Step 1-6 Steps 1-6 in the synthesis of Compound D
- Steps 1-5 follow steps 2-6 in the synthesis of compound FF
- Steps 1-5 follow steps 2-6 in the synthesis of compound FF
- Steps 1-4 Steps 2, 4-6 in the synthesis of Compound D
- Steps 1-4 Steps 2, 4-6 in the synthesis of Compound D
- Steps 1-4 Steps 2, 4-6 in the synthesis of Compound D
- Steps 5-9 Steps 1-5 in accordance with the synthesis of Compound D
- Steps 10-11 Steps 8-9 in the synthesis of Compound I
- Step 1-4 Steps 1-4 in the synthesis of compound DD
- Steps 5-9 Steps 1-5 in the synthesis of Compound D
- Steps 10-11 Steps 8-9 in the synthesis of Compound I
- Step 2-5 follow steps 3-6 in the synthesis of compound FF
- Step 1-5 Steps 1-5 in the synthesis of compound GG
- Steps 1-4 follow steps 3-6 in the synthesis of compound FF
- Step 1 Step 1 in the synthesis of compound GG
- Step 2-5 follow steps 3-6 in the synthesis of compound FF
- Step 1-5 Steps 1-5 in the synthesis of compound GG
- Step 1 follow step 1 in the synthesis of compound UU
- Step 2 follow step 1 in the synthesis of compound GG
- Step 5-7 follow steps 3-5 in the synthesis of compound FF
- TEA ⁇ HF (0.068 g, 0.56 mmol) was added to (1R,4S)-4-(5-((E)-8-((tert-butoxycarbonyl)amino)-2,2,3,3, 12,12-hexamethyl-10-oxo-4,11-dioxa-7,9-diaza-3-silatridec-8-8-en-5-yl)isoxazole-3- 6-oxo-5,7-diazaspiro[bicyclo[3.2.1]octane-2,1'-cyclopropane]-7-yl hydrogensulfate (0.102 g, 0.14 mmol) In a THF solution (2.000 mL).
- Step 9 follow step 6 in the synthesis of compound LL
- Steps 1-4 follow steps 6-9 in the synthesis of Compound I
- Steps 1-4 follow steps 6-9 in the synthesis of Compound I
- Step 1-5 Steps 1-5 in the synthesis of compound FF
- Step 2-4 follow steps 4-6 in the synthesis of compound FF
- Steps 1-4 follow steps 2-5 in the synthesis of compound FF
- Steps 1-4 follow steps 2-5 in the synthesis of compound FF
- Steps 1-4 follow steps 2-5 in the synthesis of compound FF
- Step 3-6 follow steps 2-5 in the synthesis of compound FF
- Step 2 follow step 2 in the synthesis of compound GG
- Step 3-4 follow steps 1-2 in the synthesis of compound TT
- Step 5-8 follow steps 2-5 in the synthesis of compound FF
- Step 1 follow step 2 in the synthesis of compound TT
- Step 3-6 Steps 1-4 in the synthesis of the compound PP
- Step 4-7 Steps 1-4 in the synthesis of the compound PP
- Step 2-6 follow steps 2-6 in the synthesis of compound VV
- Step 1 Step 1 in the synthesis of compound GG
- Step 2-3 follow steps 1-2 in the synthesis of compound TT
- Step 4-7 Steps 1-4 in the synthesis of the compound PP
- step 1
- Step 2-7 Steps 2-7 in the synthesis of the compound WW
- step 1
- Step 3 follow step 2 in the synthesis of compound TT
- Step 6 in accordance with step 1 in the synthesis of compound GG
- Step 7-10 Steps 1-4 in the synthesis of the compound PP
- Compound 5 was prepared according to steps 1-5 in Example 60.
- Phenyl-I3-iodanediyl-bis(2,2,2-trifluoroacetate) (3.6 g, 8.37 mmol, 1.5 eq.) was added portionwise to compound 3 (1.48 g, 5.58 mmol, 1 eq.) And a solution of ter-2-butyl prop-2-yn-1-ylcarbamate (0.86 g, 5.58 mmol, 1 eq.) in methanol (20 mL) and water (4 mL). The resulting mixture was stirred at room temperature for 4 hours. The solvent was removed under reduced pressure.
- DIPEA N,N-Diisopropylethylamine
- TSA Trypticase soy agar
- the bacterial strain used for the minimum inhibitory concentration (MIC) test was stored frozen in a -80 ° C low temperature refrigerator, and the use required to recover 2 days earlier. A small amount of frozen bacterial strain was scraped off with a sterile inoculating loop and streaked on a TSA solid medium plate, and placed in a normal atmospheric culture environment at 35 ⁇ 2 ° C for 20-24 hours.
- the liquid medium was taken out from the refrigerator at 4 ° C and left to heat at room temperature.
- the bacteria were diluted 300-fold with 1.1x CAMHB.
- Test compound for line A-H highest final test concentration of 64 ⁇ g/ml or 32 ⁇ g/ml, diluted 2 times.
- GC Growth control
- SC Sterile control
- Test compound dilution All test compounds were dissolved and diluted with dimethyl sulfoxide (DMSO). 170 ⁇ l of 3.2 mg/ml (50 ⁇ x 64 ⁇ g/ml) of the compound was transferred to the wells of column 1 of the dilution mother plate (A1-H1), and then 85 ⁇ l of DMSO was transferred to the wells of the other columns. Each compound was serially diluted 2 times (ie, 85 ⁇ l of the compound was aspirated from the wells of column 1 into the wells of column 2 and mixed, and 85 ⁇ l of the compound was aspirated from the wells of column 2 to column 3. Mix wells in the wells, then pipet 85 ⁇ l of the compound from the wells in column 3 into the wells of column 4 and mix, and so on to the wells in column 11).
- DMSO dimethyl sulfoxide
- Imipenem and ceftazidime were dissolved in 10 mM MOPS buffer. Transfer 110 ⁇ l of 50 ⁇ g/ml (12.5 ⁇ x 4 ⁇ g/ml) of imipenem or 110 ⁇ l of 100 ⁇ g/ml (12.5 ⁇ x 8 ⁇ g/ml) of ceftazidime to columns 1-11 of the addition plate, and then transfer 110 ⁇ l of MOPS buffer to Column 12.
- cover 6 test plates with a sterile cover, centrifuge in a centrifuge at 1000 rpm for 30 seconds, mix at 800 rpm on a vibrating plate for 1 minute, and place in a normal incubator at 35 ⁇ 2 ° C for 16-20 hours. .
- the inoculated bacteria were diluted from 10 -1 to 10 -7 with a liquid medium (such as 100 ⁇ l of bacterial inoculum + 900 ⁇ l of 1.1xCAMHB).
- test plates were placed on a plate reading device, and the mirrors were adjusted to observe the growth of bacteria in each well. At the same time, each test board was photographed with QCount software.
- the number of colonies of the bacterial inoculum at different dilutions on the TSA plates was counted and the bacterial inoculum was calculated.
- test compound When the test compound was tested in combination with imipenem, ceftazidime and ampicillin, imipenem was fixed at a concentration of 4 ⁇ g/ml, ceftazidime was fixed at a concentration of 8 ⁇ g/ml, and ampicillin was fixed at a concentration of 8 ⁇ g/ml.
- the bacterial inoculum in the assay plate was resuscitated from TSA and diluted in CAMHB, while a growth control (GC well) and a sterile control (SC well) were placed in the assay plate.
- the test plates were observed and cultured at 35 ⁇ 2 ° C for 16-20 hours in a conventional incubator to observe and record the minimum inhibitory concentration of each compound combination against different bacteria. See Table 1-3 for the results.
- A ⁇ 8 ⁇ g/ml
- B 8-16 ⁇ g/ml
- C 16-128 ⁇ g/ml
- A ⁇ 8 ⁇ g/ml
- B 8-16 ⁇ g/ml
- C 16-128 ⁇ g/ml
- A ⁇ 8 ⁇ g/ml
- B 8-16 ⁇ g/ml
- C 16-128 ⁇ g/ml
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims (19)
- 一种通式(I)所述的化合物或其酯、立体异构体以及药学上可接受的盐:其中,W 1选自任选取代的含有O、N和/或S的五元或6元杂芳环或-C(O)-;并且,(i)当W 1选自任选取代的含有O、N和/或S的五元或6元杂芳环时,W 1任选地被C 1-C 12烷基取代,W 2选自:a.Hb. 其中R 1选自 其中R 2、R 3、R 4、R 4’、R 5或R 6各自独立地选自H、C 1-C 12烷基、氨基C 1-C 12烷基、C 1-C 12烷胺基C 1-C 12烷基、 Ra和Rb各自独立地选自H、C 1-C 12烷基、C 3-C 8环烷基、OH、-OC 1-C 12烷基、-NH 2、-NHC 1-C 12烷基、-N(C 1-C 12烷基) 2、-SH、-SC 1-C 12烷基、-S(O)C 1-C 12烷基、-S(O 2)C 1-C 12烷基、-SO 3H;R 7和R 7’各自独立地选自-NH 2、-NHC 1-C 12烷基、-N(C 1-C 12烷基) 2、-OC 1-C 12烷基、-SC 1-C 12烷基;R 8和R 8’各自独立地选自NH、-NC 1-C 12烷基、O、S;R 9和R 9’各自独立地选自-NH-、-N(C 1-C 12烷基)-、-O-、-S-;Z 1选自CR 10R 11或NR 12,R 10、R 11和R 12各自独立地选自H、NH 2、 其中R 13和R 15各自独立地选自-NH 2、-NHC 1-C 12烷基、 -N(C 1-C 12烷基) 2、-OC 1-C 12烷基、-SC 1-C 12烷基;R 14和R 16各自独立地选自NH、-NHC 1-C 12烷基、O、S;R 17选自-NH-、-N(C 1-C 12烷基)-、-O-、-S-;i、j、k、l、m、n、p、q、r和s各自独立地选自0、1、2、3、4、5或6;条件是q和r不同时为0;R 1’选自H、C 1-C 12烷基、C 3-C 8环烷基、OH、-OC 1-C 12烷基、-NH 2、-NHC 1-C 12烷基、-N(C 1-C 12烷基) 2、-SH、-SC 1-C 12烷基、-S(O)C 1-C 12烷基、-S(O 2)C 1-C 12烷基、-SO 3H;c. 其中Z 2选自CR 18R 19或NR 20,R 18、R 19和R 20各自独立地选自H、NH 2或 其中R 21选自-NH 2、-NHC 1-C 12烷基、-N(C 1-C 12烷基) 2、-OC 1-C 12烷基、-SC 1-C 12烷基;R 22选自NH、-NHC 1-C 12烷基、O、S;t、u和w各自独立地选自1、2、3、4、5或6,条件是t和u不同时为0;d. 其中Z 3和Z 4各自独立地选自-NR 25-、-O-,R 23和R 24各自独立地选自H、C 1-C 12烷基,或者R 23和R 24一起形成=O或=NH;R 25选自H、氨基C 1-C 12烷基或C 1-C 12烷胺基C 1-C 12烷基;(ii)当W 1选自-C(O)-时,W 2选自-OR 26、-NHR 27,其中R 26和R 27各自独立地选自H、C 1-C 12烷基或 其中Z 5选自CR 28R 29或NR 30,R 28、R 29和R 30各自独立地选自H、NH 2或 其中R 31选自-NH 2、-NHC 1-C 12烷基、-N(C 1-C 12烷基) 2、-OC 1-C 12烷基、 -SC 1-C 12烷基;R 32选自NH、NC 1-C 12烷基、O、S;x、y和z各自独立地选自1、2、3、4、5或6,条件是x和y不同时为0;W 3选自-SO 3M、-OSO 3M、-OSO 2NH 2、-OPO 3M、-OCR 33R 34CO 2M、-OCR 35R 36SO 3M、-OCR 37R 38PO 3M;其中,M选自H或药学上可接受的阳离子;R 33、R 34、R 35、R 36、R 37和R 38各自独立地选自H、C 1-C 12烷基、卤素。
- 根据权利要求2所述的化合物或其酯、立体异构体以及药学上可接受的盐,其中,W 1选自任选取代的含有O、N和/或S的五元或6元杂芳环;W 2选自:a.Hb. 其中R 1选自 其中R 2、R 3、R 4、R 4’、R 5或R 6各自独立地选自H、C 1-C 12烷基、氨基C 1-C 12烷基、C 1-C 12烷胺基C 1-C 12烷基、 Ra和Rb各自独立地选自H、C 1-C 12烷基、OH、-OC 1-C 12烷基、-NH 2、-NHC 1-C 12烷基、-N(C 1-C 12烷基) 2、-SH、-SC 1-C 12烷基、-S(O)C 1-C 12烷基、-S(O 2)C 1-C 12烷基、-SO 3H;R 7和R 7’各自独立地选自-NH 2、-NHC 1-C 12烷基、-N(C 1-C 12烷基) 2、-OC 1-C 12烷基、 -SC 1-C 12烷基;R 8和R 8’各自独立地选自NH、-NC 1-C 12烷基、O、S;R 9和R 9’各自独立地选自-NH-、-N(C 1-C 12烷基)-、-O-、-S-;Z 1选自CR 10R 11或NR 12,R 10、R 11和R 12各自独立地选自H、NH 2、 其中R 13和R 15各自独立地选自-NH 2、-NHC 1-C 12烷基、-N(C 1-C 12烷基) 2、-OC 1-C 12烷基、-SC 1-C 12烷基;R 14和R 16各自独立地选自NH、-NHC 1-C 12烷基、O、S;R 17选自-NH-、-N(C 1-C 12烷基)-、-O-、-S-;i、j、k、l、m、n、p、q、r和s各自独立地选自0、1、2、3、4、5或6;条件是q和r不同时为0;R 1’选自H、C 1-C 12烷基、C 3-C 8环烷基、OH、-OC 1-C 12烷基、-NH 2、-NHC 1-C 12烷基、-N(C 1-C 12烷基) 2、-SH、-SC 1-C 12烷基、-S(O)C 1-C 12烷基、-S(O 2)C 1-C 12烷基、-SO 3H;c. 其中Z 2选自CR 18R 19或NR 20,R 18、R 19和R 20各自独立地选自H、NH 2或 其中R 21选自-NH 2、-NHC 1-C 12烷基、-N(C 1-C 12烷基) 2、-OC 1-C 12烷基、-SC 1-C 12烷基;R 22选自NH、-NHC 1-C 12烷基、O、S;t、u和w各自独立地选自1、2、3、4、5或6,条件是t和u不同时为0;
- 根据权利要求1-3中任一项所述的化合物或其酯、立体异构体以及药学上可接受的盐,其中,W 1选自呋喃环、吡咯环、吡唑环、咪唑环、三唑环、噻吩环、噻唑环、异噻唑环、噁唑环、异噁唑环、1,2,4-噁二唑环、1,3,4-噁二唑环;吡啶环、嘧啶基、三嗪环、吡嗪环、四唑环、哒嗪环、噻二唑环;M选自H、钠离子、钾离子、钙离子、镁离子、NH 4 +、N(C 1-C 12烷基) 4 +。
- 根据权利要求6所述的化合物或其药学上可接受的盐,其中W 1选自噁唑环、异噁唑环、1,2,4-噁二唑环、1,3,4-噁二唑环。
- 根据权利要求1所述的化合物或其药学上可接受的盐,其选自:(1R,4S)-4-(1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1] 辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(氨基甲基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(胍基甲基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-氨基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-胍基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(3-氨基丙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸钠;(1R,4S)-4-(5-(4-氨基丁基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-亚胺基咪唑烷-4-基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-氨基-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-胍基-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((R)-2-胍基-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((S)-2-胍基-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(1-(胍基甲基)环丙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((氮杂环丁烷-3-基氨基)甲基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(胍基甲基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((1-甲基胍基)甲基)异噁唑-3-yl)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7基硫酸;(1R,4S)-4-(5-(氨基甲基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((甲基氨基)甲基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-胍基乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-(1-甲基胍基)乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-胍基-1-羟基乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((S)-2-胍基-1-羟基乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((R)-2-胍基-1-羟基乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-氨基乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-(甲基氨基)乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-6-氧代-4-(5-(哌啶-4-基)异噁唑-3-基)-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-6-氧代-4-(5-(哌啶-3-基)异噁唑-3-基)-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-6-氧代-4-(5-(吡咯烷-3-基)异噁唑-3-基)-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-6-氧代-4-(5-(2-(哌啶-4-基氨基)乙基)异噁唑-3-基)-5,7- 二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-((1-脒基哌啶-4-基)氨基)乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((1s,3R)-3-氨基环丁基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((1r,3S)-3-氨基环丁基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((1R,3S)-3-氨基环戊基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((1R,3R)-3-氨基环戊基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(((1r,3R)-3-氨基环丁基)甲基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(((1s,3S)-3-氨基环丁基)甲基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((1-氨基环丙基)甲基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((1-(甲基氨基)环丙基)甲基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(氮杂环丁烷-3-基甲基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-(甲基氨基)乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((氮杂环丁烷-3-基氨基)甲基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(氮杂环丁烷-3-基甲基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((氮杂环丁烷-3-基氧基)甲基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(((1-脒基氮杂环丁烷-3-基)氨基)甲基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(3-氨基环丁基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((1s,3S)-3-氨基环丁基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((1r,3R)-3-氨基环丁基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-((2-胍基乙基)氨基)乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-6-氧代-4-(哌啶-4-基氨基甲酰基)-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-6-氧代-4-(吡咯烷-3-基氨基甲酰基)-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(氮杂环丁烷-3-基氨基甲酰基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((S)-1-羟基-2-((2-(甲基氨基)乙基)氨基)乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((S)-2-((2-氨基乙基)氨基)-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((S)-2-亚胺基咪唑烷-4-基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((R)-2-亚氨基咪唑烷-4-基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;2-(((1R,4S)-4-(5-(氨基甲基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基)氧基)乙酸;2-(((1R,4S)-4-(5-(((叔丁氧羰基)氨基)甲基)异噁唑-3-基)-6-氧代 -5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基)氧基)乙酸;2-(((1R,4S)-4-(5-(氨基甲基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基)氧基)-2,2-二氟乙酸;2-(((1R,4S)-4-(5-(((叔丁氧羰基)氨基)甲基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基)氧基)-2,2-二氟乙酸;(1R,4S)-4-(5-((1s,3R)-3-胍基环丁基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(1-羟基-2-((2-(甲基氨基)乙基)氨基)乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((S)-1-羟基-2-((2-(甲基氨基)乙基)氨基)乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((R)-1-羟基-2-((2-(甲基氨基)乙基)氨基)乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-((2-氨基乙基)氨基)-1-羟基乙基)异噁唑-3-y1)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((S)-2-((2-氨基乙基)氨基)-1-羟基乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((R)-2-((2-氨基乙基)氨基)-1-羟基乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-((2-胍基乙基)氨基)-1-羟基乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((S)-2-((2-胍基乙基)氨基)-1-羟基乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((R)-2-((2-胍基乙基)氨基)-1-羟基乙基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(1-羟基-2-((2-(甲基氨基)乙基)氨基)乙基)-1,3,4-噁 二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((R)-1-羟基-2-((2-(甲基氨基)乙基)氨基)乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-((2-氨基乙基)氨基)-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((R)-2-((2-氨基乙基)氨基)-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-((2-胍基乙基)氨基)-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((S)-2-((2-胍基乙基)氨基)-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((R)-2-((2-胍基乙基)氨基)-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-(氮杂环丁烷-3-基氨基)-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(1-羟基-2-(甲基氨基)乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(1-羟基-2-(吡咯烷-3-基氨基)乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-(二甲基氨基)-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(羟基(吡咯烷-2-基)甲基)-1,3,4-噁二唑-2-yl)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;2-羟基-N,N,N-三甲基-2-(5-((1R,4S)-6-氧代-7-(磺氧基)-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-4-基)-1,3,4-噁二唑-2-基)乙烷-1-铵;(1R,4S)-4-(5-(1-羟基-2-(哌啶-4-基氨基)乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(4-羟基哌啶-4-基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(1-脒基哌啶-4-基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-6-氧代-4-(5-(哌嗪-1-基)异噁唑-3-基)-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-6-氧代-4-(5-(2-氧代哌嗪-1-基)异噁唑-3-基)-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(L-脯氨酰基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((S)-2-((2-(二甲基氨基)乙基)氨基)-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;2-(((2S)-2-羟基-2-(5-((1R,4S)-6-氧代-7-(磺氧基)-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-4-基)-1,3,4-噁二唑-2-基)乙基)氨基)-N,N,N-三甲基乙烷-1-铵;(1R,4S)-6-氧代-4-(5-(2-氧代咪唑烷-4-基)-1,3,4-噁二唑-2-基)-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-6-氧代-4-(5-(2-氧代噁唑烷-5-基)-1,3,4-噁二唑-2-基)-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-6-氧代-4-(5-(2-氧代噁唑烷-4-基)-1,3,4-噁二唑-2-基)-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-亚胺基-1-((甲基氨基)甲基)咪唑烷-4-基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7- 基硫酸;(1R,4S)-4-(5-(1-((二甲基氨基)甲基)-2-亚胺基咪唑烷-4-基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;1-(2-亚胺基-4-(5-((1R,4S)-6-氧代-7-(磺氧基)-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-4-基)-1,3,4-噁二唑-2-基)咪唑烷-1-基)-N,N,N-三甲基甲烷铵;(1R,4S)-4-(5-(2-亚胺基-1-((甲基氨基)甲基)-5-氧代咪唑烷-4-基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(5-羟基-2-亚胺基-1-((甲基氨基)甲基)咪唑烷-4-基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(3-((甲基氨基)甲基)-2-氧代噁唑烷-4-基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(1-(氨基甲基)-2-亚胺基咪唑烷-4-基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(5-氨基-2-亚胺基咪唑烷-4-基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(2-亚胺基-5-(甲基氨基)咪唑烷-4-基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-(5-(二甲基氨基)-2-亚胺基咪唑烷-4-基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((R)-2-氨基-1-羟乙基)-1,3,4-噁二唑-2-基-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((S)-2-氨基-1-羟乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((S)-1-羟基-2-(甲基氨基)乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;(1R,4S)-4-(5-((S)-2-(二甲基氨基)-1-羟基乙基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基硫酸;2-(((1R,4S)-4-(5-(氨基甲基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基)氧基)乙酸;2-(((1R,4S)-4-(5-(((叔丁氧羰基)氨基)甲基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基)氧基)乙酸;2-(((1R,4S)-4-(5-(氨基甲基)-1,3,4-噁二唑-2-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基)氧基)-2,2-二氟乙酸;2-(((1R,4S)-4-(5-(((叔丁氧羰基)氨基)甲基)异噁唑-3-基)-6-氧代-5,7-二氮杂螺环[双环[3.2.1]辛烷-2,1′-环丙烷]-7-基)氧基)-2,2-二氟乙酸。
- 一种药物组合物,其包含权利要求1-9中任一项所述的化 合物以及药学上可接受的赋形剂。
- 根据权利要求12所述的药物组合物,其还包括一种或多种β内酰胺类抗生素。
- 根据权利要求13所述的药物组合物,其中所述β内酰胺类抗生素选自青霉素类抗生素、头孢菌素类抗生素、单内酰胺环类抗生素、碳青霉烯类抗生素、青霉烯类酶抑制剂。
- 根据权利要求1-9中任一项所述的化合物在制备用于治疗细菌感染导致的疾病中的药物中的用途。
- 根据权利要求15所述的用途,其中所述药物进一步包含β内酰胺类抗生素。
- 根据权利要求15所述的用途,其中所述细菌选自枸橼酸杆菌、弗氏柠檬酸杆菌、阴沟肠杆菌、肺炎克雷伯氏菌、大肠杆菌、普通变形杆菌、沙门氏菌、粘质沙雷氏菌、志贺氏杆菌、铜绿假单胞菌、黏膜炎莫拉菌、淋病奈瑟球菌、脑膜炎奈瑟球菌、不动杆菌、伯克氏菌、弯曲杆菌、幽门螺杆菌、霍乱弧菌、克雷伯杆菌、流感嗜血杆菌、鸟复合分支杆菌、脓肿分支杆菌、堪萨斯分支杆菌、溃疡分支杆菌、肺炎嗜衣原体、沙眼衣原体、β-溶血性链球菌、鲍氏不动杆菌、绿农假单胞菌、绿浓杆菌、脆弱拟杆菌、蜡样芽胞杆菌和嗜麦芽窄食单胞菌中的一种或多种。
- 根据权利要求15所述的用途,其中所述疾病选自呼吸道感染、尿道感染、中枢神经系统感染、耳部感染、胸膜肺和支气管感染、腹腔内感染、心血管感染、皮肤或软组织感染、骨与关节感染、生殖器感染、眼部感染、咽部感染、口腔感染中的一种或多种。
- 根据群里要求18所述的用途,其中所述疾病选自上呼吸道感染、下呼吸道感染、气管炎、支气管炎、肺炎、肺结核、咽炎、复杂性尿道感染、并发性尿道感染、非并发性尿道感染、膀胱炎、肾盂肾炎、脑炎、脑膜炎、脑脓肿、外耳炎、中耳炎、血液感染例如败血症或菌血症、心内膜炎、心肌炎、心包炎、关节炎、骨髓炎、生殖器溃疡、阴道炎、子宫颈炎、结膜炎、角膜炎、眼内炎、咽炎、 牙龈炎中的一种或多种。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201980010129.1A CN111670187B (zh) | 2018-01-25 | 2019-01-24 | β-内酰胺酶抑制剂及其用途 |
EP19743504.3A EP3744722A4 (en) | 2018-01-25 | 2019-01-24 | Ss-LACTAMASE INHIBITOR AND ITS USE |
JP2020540565A JP7273420B2 (ja) | 2018-01-25 | 2019-01-24 | β-ラクタマーゼ阻害剤及びその用途 |
KR1020207024397A KR20200113247A (ko) | 2018-01-25 | 2019-01-24 | β-락타마제 억제제 및 그 용도 |
CA3089150A CA3089150A1 (en) | 2018-01-25 | 2019-01-24 | .beta.-lactamase inhibitor and use thereof |
AU2019211693A AU2019211693B2 (en) | 2018-01-25 | 2019-01-24 | Beta-lactamase inhibitor and use thereof |
US16/998,577 US11078202B2 (en) | 2018-01-25 | 2020-08-20 | β-lactamase inhibitor and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2018/074185 | 2018-01-25 | ||
CN2018074185 | 2018-01-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/964,416 A-371-Of-International US20210046057A1 (en) | 2018-01-25 | 2019-01-24 | Beta-lactamase inhibitor and use thereof |
US16/998,577 Continuation US11078202B2 (en) | 2018-01-25 | 2020-08-20 | β-lactamase inhibitor and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019144912A1 true WO2019144912A1 (zh) | 2019-08-01 |
Family
ID=67394549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2019/073000 WO2019144912A1 (zh) | 2018-01-25 | 2019-01-24 | β-内酰胺酶抑制剂及其用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US11078202B2 (zh) |
EP (1) | EP3744722A4 (zh) |
JP (1) | JP7273420B2 (zh) |
KR (1) | KR20200113247A (zh) |
CN (1) | CN111670187B (zh) |
AU (1) | AU2019211693B2 (zh) |
CA (1) | CA3089150A1 (zh) |
WO (1) | WO2019144912A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023088375A1 (zh) | 2021-11-17 | 2023-05-25 | 苏州信诺维医药科技股份有限公司 | β-内酰胺酶抑制剂中间体及制备方法 |
CN116730941A (zh) * | 2023-06-15 | 2023-09-12 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 5-苯基-1,3,4-恶二唑类化合物及其制备方法和应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200113247A (ko) | 2018-01-25 | 2020-10-06 | 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. | β-락타마제 억제제 및 그 용도 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1033000A (en) | 1910-12-14 | 1912-07-16 | Joseph Leslie Forster | Pneumatic piano-player. |
US1098129A (en) | 1910-04-05 | 1914-05-26 | John Thomas Simpson | Aeroplane. |
US1337809A (en) | 1917-06-22 | 1920-04-20 | Winton Alexander | Protecting means for vessels |
CN101918407A (zh) * | 2008-01-18 | 2010-12-15 | 默沙东公司 | β-内酰胺酶抑制剂 |
WO2013030735A1 (en) | 2011-08-30 | 2013-03-07 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections |
WO2013149121A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
CN104334555A (zh) * | 2012-03-30 | 2015-02-04 | 丘比斯特药物股份有限公司 | 异噁唑β-内酰胺酶抑制剂 |
WO2015110963A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | 2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane derivatives and their use as antibacterial agents |
WO2015150890A1 (en) | 2014-03-29 | 2015-10-08 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo [3.2.1] oct-6-yl}ester |
WO2015159265A1 (en) | 2014-04-18 | 2015-10-22 | Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
WO2015173665A1 (en) | 2014-05-14 | 2015-11-19 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-[5-(3-azetidinylamino)-methyl-[1,3,4]- oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo[3.2.1] oct-6-yl} ester trifluoroacetate |
WO2015173663A1 (en) | 2014-05-14 | 2015-11-19 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-[5-(2-methylamino-ethyl)-[1,3,4]-oxadiazol-2-yl]-7-oxo-1,6-diaza-bicyclo [3.2.1]oct-6-yl} ester |
WO2017055922A1 (en) | 2015-10-02 | 2017-04-06 | Legochem Biosciences, Inc. | Compositions and methods for inhibiting beta-lactamase |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200113247A (ko) | 2018-01-25 | 2020-10-06 | 쑤저우 시노벤트 파마슈티칼즈 씨오., 엘티디. | β-락타마제 억제제 및 그 용도 |
-
2019
- 2019-01-24 KR KR1020207024397A patent/KR20200113247A/ko not_active Application Discontinuation
- 2019-01-24 CN CN201980010129.1A patent/CN111670187B/zh active Active
- 2019-01-24 JP JP2020540565A patent/JP7273420B2/ja active Active
- 2019-01-24 CA CA3089150A patent/CA3089150A1/en active Pending
- 2019-01-24 WO PCT/CN2019/073000 patent/WO2019144912A1/zh unknown
- 2019-01-24 EP EP19743504.3A patent/EP3744722A4/en active Pending
- 2019-01-24 AU AU2019211693A patent/AU2019211693B2/en active Active
-
2020
- 2020-08-20 US US16/998,577 patent/US11078202B2/en active Active
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1098129A (en) | 1910-04-05 | 1914-05-26 | John Thomas Simpson | Aeroplane. |
US1033000A (en) | 1910-12-14 | 1912-07-16 | Joseph Leslie Forster | Pneumatic piano-player. |
US1337809A (en) | 1917-06-22 | 1920-04-20 | Winton Alexander | Protecting means for vessels |
CN101918407A (zh) * | 2008-01-18 | 2010-12-15 | 默沙东公司 | β-内酰胺酶抑制剂 |
WO2013030735A1 (en) | 2011-08-30 | 2013-03-07 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan- 7 - one derivatives and their use in the treatment of bacterial infections |
CN103649088A (zh) * | 2011-08-30 | 2014-03-19 | 沃克哈特有限公司 | 1,6-二氮杂双环[3,2,1]辛-7-酮衍生物及其在治疗细菌感染中的用途 |
CN104334555A (zh) * | 2012-03-30 | 2015-02-04 | 丘比斯特药物股份有限公司 | 异噁唑β-内酰胺酶抑制剂 |
WO2013149121A1 (en) | 2012-03-30 | 2013-10-03 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
US20130296290A1 (en) | 2012-03-30 | 2013-11-07 | Cubist Pharmaceuticals, Inc. | 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors |
WO2014141132A1 (en) | 2013-03-14 | 2014-09-18 | Naeja Pharmaceutical Inc. | NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS |
WO2015110963A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | 2-(1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane derivatives and their use as antibacterial agents |
WO2015150890A1 (en) | 2014-03-29 | 2015-10-08 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-(5-(3-amino-propyl)-[1,3,4]oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo [3.2.1] oct-6-yl}ester |
WO2015159265A1 (en) | 2014-04-18 | 2015-10-22 | Wockhardt Limited | Pharmaceutical compositions comprising antibacterial agents |
WO2015173665A1 (en) | 2014-05-14 | 2015-11-19 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-[5-(3-azetidinylamino)-methyl-[1,3,4]- oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo[3.2.1] oct-6-yl} ester trifluoroacetate |
WO2015173663A1 (en) | 2014-05-14 | 2015-11-19 | Wockhardt Limited | A process for preparation of trans-sulfuric acid mono-{2-[5-(2-methylamino-ethyl)-[1,3,4]-oxadiazol-2-yl]-7-oxo-1,6-diaza-bicyclo [3.2.1]oct-6-yl} ester |
WO2017055922A1 (en) | 2015-10-02 | 2017-04-06 | Legochem Biosciences, Inc. | Compositions and methods for inhibiting beta-lactamase |
Non-Patent Citations (2)
Title |
---|
GREENE, T.W.WUTS, P.G.M.: "Greene's Protective Groups in Organic Synthesis,", JOHN WILEY AND SONS |
See also references of EP3744722A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023088375A1 (zh) | 2021-11-17 | 2023-05-25 | 苏州信诺维医药科技股份有限公司 | β-内酰胺酶抑制剂中间体及制备方法 |
CN116730941A (zh) * | 2023-06-15 | 2023-09-12 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 5-苯基-1,3,4-恶二唑类化合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CA3089150A1 (en) | 2019-01-24 |
AU2019211693B2 (en) | 2023-12-21 |
AU2019211693A1 (en) | 2020-09-03 |
KR20200113247A (ko) | 2020-10-06 |
CN111670187A (zh) | 2020-09-15 |
US20210032260A1 (en) | 2021-02-04 |
JP7273420B2 (ja) | 2023-05-15 |
CN111670187B (zh) | 2021-04-16 |
JP2021511351A (ja) | 2021-05-06 |
EP3744722A4 (en) | 2021-11-03 |
US11078202B2 (en) | 2021-08-03 |
EP3744722A1 (en) | 2020-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI773687B (zh) | β內醯胺酶抑制劑化合物 | |
US11078202B2 (en) | β-lactamase inhibitor and use thereof | |
WO2018177302A1 (zh) | 含氮杂环取代的苯并噁嗪噁唑烷酮类化合物及其制备方法和用途 | |
TW200530255A (en) | 3-pyridiniummethylcefem compound | |
JP2022097520A (ja) | 複素環式化合物及び細菌感染症の予防又は治療におけるそれらの使用 | |
TW201731844A (zh) | 羥基烷基噻二唑衍生物 | |
JP5662940B2 (ja) | 新規な抗微生物薬 | |
WO2015192714A1 (zh) | 吡咯并咪唑环衍生物及其在医药上的应用 | |
CN109415365B (zh) | 卡巴培南化合物 | |
WO2023011574A1 (zh) | 芳香乙炔类衍生物及其制备方法和用途 | |
US20120058989A1 (en) | Antibacterial fluoroquinolone analogs | |
RU2162088C2 (ru) | 1-метилкарбапенем или его фармакологически приемлемые соли, композиция, способ предупреждения или лечения бактериальных инфекций | |
WO2017189866A1 (en) | Polymyxin analogs useful as antibiotic potentiators | |
US20060247286A1 (en) | Oxazolidinone antibiotics and derivatives thereof | |
KR20180022917A (ko) | 설핀일 또는 설폰일을 갖는 3환성 화합물 | |
WO1996001261A1 (fr) | Nouveau derive de carbapeneme | |
US20210046057A1 (en) | Beta-lactamase inhibitor and use thereof | |
TW202007689A (zh) | 雜環化合物及它們在預防或治療細菌感染中的應用 | |
KR20000048687A (ko) | 피리도벤족사진 유도체 | |
WO2024067813A1 (zh) | 芳香乙炔类衍生物及其制备方法和其医药上的用途 | |
JP2004203809A (ja) | 新規ビフェニル誘導体 | |
TW201840322A (zh) | 羥烷基噻二唑衍生物之n-膦醯基氧基甲基前驅藥 | |
TW202421162A (zh) | 氧基取代化合物 | |
JPH0343272B2 (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19743504 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3089150 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020540565 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20207024397 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019211693 Country of ref document: AU Date of ref document: 20190124 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019743504 Country of ref document: EP Effective date: 20200825 |